Plasma vasoactive intestinal polypeptide and other regulatory peptides in children with neurogenic tumours

Area of Science:

• Pediatric Oncology
• Endocrinology
• Biomarkers

Background:

• Neurogenic tumors are a significant concern in pediatric oncology.
• Identifying reliable diagnostic markers for pediatric neurogenic tumors is crucial for early detection and treatment.
• Plasma regulatory peptides are increasingly explored as potential biomarkers.

Purpose of the Study:

• To investigate plasma regulatory peptide levels in children diagnosed with neurogenic tumors.
• To compare these levels against control groups, including healthy children and those with other tumor types.
• To determine if specific peptide levels correlate with the presence of neurogenic tumors.

Main Methods:

• Blood samples were collected from 21 children with neurogenic tumors and 22 control children.
• Plasma levels of vasoactive intestinal polypeptide (VIP), gastrin, pancreatic glucagon, and pancreatic polypeptide were measured.
• Statistical analysis was performed to compare peptide levels between groups.

Main Results:

• Plasma VIP levels were significantly higher in children with neurogenic tumors compared to both normal children and those with other tumors (p < 0.05).
• No significant differences were observed in plasma levels of gastrin, pancreatic glucagon, or pancreatic polypeptide among the studied groups.
• The findings suggest a specific association between elevated VIP and pediatric neurogenic tumors.

Conclusions:

• Elevated plasma VIP levels represent a potential diagnostic marker for neurogenic tumors in children.
• VIP's role in the pathophysiology or as a marker for neurogenic tumors warrants further investigation.
• This study highlights the potential of using peptide biomarkers for improved pediatric cancer diagnostics.